Gaboxadol
From Self-sufficiency
| File:Gaboxadol.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one | |
| Identifiers | |
| CAS Number | 64603-91-4 |
| ATC code | none |
| PubChem | CID 3448 |
| Chemical data | |
| Formula | C6H8N2O2 |
| Molar mass | 140.14 g/mol[[Script error: No such module "String".]] |
Gaboxadol is an experimental sleep aid drug developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way from benzodiazepines and Z-drugs (zolpidem, zaleplon, etc).{{fact} Lundbeck states that gaboxadol also increases deep sleep (stage 4).
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
| 40x30px | This sedative-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Sedatives
- Isoxazolopyridines
- Lactams
- Sedative stubs
